17th Annual Pain Therapeutics London, England, UK 22-23 May 2017

Description:
Created with an expert scientific advisory board, Pain Therapeutics 2017 will hone in on the latest innovations and novel approaches to pain therapy and analgesic drugs as well as look at the practicalities of using animal models and translational biomarkers in pain research.

Aimed at an audience of scientific leaders and senior specialists in neuroscience, CNS, clinical operations and pharmacology, presentations from a selection of hand-picked pharmaceutical companies currently developing novel treatments in pain, will keep attendees at the forefront of medical breakthroughs to adapt to the growing need towards minimising opioid dependency and new drug discovery.

Exclusive new findings from phase II clinical trials will be just some of the highlights at the 17th annual show when it returns to London this spring.

KEYNOTE SPEAKERS INCLUDE:

. Anthony Jones, Prof of Neuro-Rheumatology, University of Manchester
. Dr Steven Kamerling, Therapeutic Area Head for Pain, Inflammation and Oncology, Zoetis
. Dr Joseph W. Stauffer, CMO, Cara Therapeutics
. Dr Stephen Doberstein, Senior VP and CSO, Nektar Pharmaceuticals
. Dr Iain Chessell, Head of Neuroscience, AstraZeneca
. Dr Randall Stevens, CMO, Centrexion Therapeutics
. Dr Richard Butt, CEO, Apollo Therapeutics

Price:
Conference + 1 Workshop: GBP 2098
Conference: GBP 1499